Press Releases

All News

News TypeNewsPress Releases

By Year

• November 18, 2025 \ Nuvig Therapeutics Appoints Celia J.F. Lin, M.D., as Chief Medical Officer
• September 9, 2025 \ Nuvig Therapeutics Appoints David J. Woodhouse, Ph.D., as Chief Executive Officer and James Mackay, Ph.D., as Independent Board Chair
• May 14, 2025 \ Nuvig Therapeutics Announces First Patient Dosed in Phase 2 CIDP Trial of NVG-2089 and Presentation of Phase 1 Data
• December 5, 2024 \ Nuvig Therapeutics Announces $161 Million Series B Financing and Progression to Phase 2 Development with Novel, Second-Generation Immunomodulator
• February 12, 2024 \ Nuvig Initiates Clinical Development of Next-Generation Immune Modulator NVG-2089
• October 4, 2023 \ Nuvig Therapeutics Appoints Dr. Alan Glicklich Chief Medical Officer
• May 11, 2022 \ Nuvig Launches to Develop Novel Immune Therapeutics for Chronic Inflammatory and Autoimmune Diseases

reCAPTCHA

Recaptcha requires verification.

protected by reCAPTCHA